Usefulness of clinical study of irinotecan and cisplatin for recurrent ovarian cancer
Yahagi, N.; Kobayashi, Y.; Ohara, T.; Kondo, H.; Suzuki, N.; Kiguchi, K.; Ishizuka, B.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(13): 2583-2586
2009
ISSN/ISBN: 0385-0684 PMID: 20009459 Document Number: 633843
So far, there is no recommended evidence-based chemotherapeutic regimen for recurrent or refractory ovarian carcinoma in the guideline. In our institute, combination chemotherapy of CPT-11 and CDDP (CPT-P) was administered for recurrent or refractory ovarian carcinoma patients previously treated with regimens including taxane. In fourteen cases treated with CPT-P, there were 2 cases of CR, 2 of PR, 3 of SD, and 7 of PD. Overall response rate was 28. 5%, and the median progression-free interval was 5.5 months. No severe side effect was observed except in one patient in whom chemotherapy was discontinued due to grade 4 neutropenia and grade 3 diarrhea. Thus CPT-P seemed to be effective and safe for the recurrent or refractory ovarian carcinoma previously treated with taxane-included regimen.